Table of Contents
What changed
Revenue was effectively unchanged at NZD 309.4m versus NZD 309.3m. Below the top line the deterioration was sharp: EBITDA fell 46.0% to NZD 30.5m, PBT fell 59.6% to NZD 18.3m, and reported attributable NPAT collapsed 85.0% to NZD 3.9m. The headline NPAT decline overstates the operating deterioration — profit from continuing operations was NZD 14.3m, with the balance absorbed by non-controlling interests; the effective tax rate was stable at roughly 22% in both periods, so PBT down 59.6% is the cleaner operating read.
The segment picture explains most of the earnings damage. Horticulture swung from a NZD 15.2m segment profit to a NZD 2.1m loss on slightly higher revenue, a roughly NZD 17.3m reversal. Global Proteins held its result almost flat at NZD 30.3m on NZD 151.1m of revenue, and Logistics contributed NZD 2.3m (prior: NZD 3.5m). The Other/corporate bucket carried a NZD 12.2m loss.
Operating cash flow improved to an outflow of NZD 23.9m from an outflow of NZD 30.6m, but pre-lease free cash flow was still negative NZD 28.7m. Gross borrowings rose to NZD 67.5m from NZD 39.4m, lifting net debt to NZD 29.8m from NZD 3.2m — around 1.0x EBITDA versus effectively nil.
What matters
- Horticulture has reset, not just dipped. A NZD 17.3m swing on broadly flat segment revenue implies a margin, cost, or pricing problem rather than a volume shortfall, and the release references cyclone impacts on logistics volumes as well. Without a return to normalised Horticulture economics, group EBITDA cannot rebuild off the Proteins segment alone.
- Leverage direction has turned. Net debt/EBITDA moving from 0.06x to 0.98x in a seasonally cash-absorptive half is not yet stretched, but the combination of higher inventory (up 20.6% to NZD 46.7m) and a second negative FCF half leaves less slack than the prior year.
- Non-controlling interests now absorb a much larger share of profit. Continuing-operations profit of NZD 14.3m versus attributable NPAT of NZD 3.9m means roughly NZD 10.4m accrued to minorities, versus a far smaller gap prior. That changes the economic read for shareholders even before the segment result is debated.
Expectations
No quantitative guidance, forward-work balance, or stated targets were provided in the supplied materials. Seasonally, HY22 delivered roughly 82% of FY22 EBITDA and 134% of FY22 NPAT, with the second half actually loss-making at the NPAT line. On that shape, the current HY23 EBITDA base of NZD 30.5m leaves little cushion for a weak second half, and annualised HY23 revenue of NZD 618.7m is essentially flat to FY22's NZD 619.2m. The release does not support a bridge back to prior-period earnings within the current half, and it does not quantify what Horticulture recovery looks like.
Quality of result
Earnings quality deteriorated. Cash conversion weakened — operating cash flow to EBITDA moved to -78.5% from -54.2% — so the smaller operating outflow is partly a denominator effect rather than improved working-capital discipline. Inventory days rose to 27.5 from 22.8, consistent with inventory building into the second half, and pre-lease FCF was negative NZD 28.7m. The Proteins result looks durable at ~20% segment margin, but group EBITDA is flattered by the fact that Horticulture's swing to loss was not larger, and there is no disclosed one-off in the supplied excerpts to separate timing from run-rate. Underlying NPAT of NZD 14.5m is disclosed versus reported NPAT, but no reconciliation bridge was provided.
Unresolved
- What specifically caused Horticulture to move from NZD 15.2m profit to a NZD 2.1m loss — apple pricing, yield, cost inflation, FX, or cyclone-related write-downs — and how much is expected to reverse.
- Whether the NZD 28.1m rise in gross borrowings funds normal seasonal inventory build or reflects a structural shift in working-capital intensity.
- What the full-year dividend intention is; only FY22's second instalment of 3.5 cents is referenced in the supplied materials, and no current-period dividend was extracted.
- How the underlying NPAT of NZD 14.5m reconciles to reported NPAT of NZD 3.9m, given no adjustment bridge was supplied.
This briefing cannot assess forward earnings power because no guidance, forward-work balance, or quantified Horticulture recovery path was provided in the supplied materials.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $309.4m | $309.3m | flat |
| EBITDA | $30.5m | $56.4m | -46.0% ↓ |
| Net profit after tax | $3.9m | $26.1m | -85.0% ↓ |
| Net cash inflow from operating activities | −$23.9m | −$30.6m | +21.8% ↑ |
| Operating profit | $20.5m | $46.8m | -56.3% ↓ |
| Profit before tax | $18.3m | $45.3m | -59.6% ↓ |
| Total assets | $619.7m | $664.5m | -6.7% ↓ |
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Global Proteins | $151.1m | $151.7m | $30.3m | -0.2pp |
| Horticulture | $122.6m | $117.3m | −$2.1m | +1.7pp |
| Logistics | $35.2m | $40.5m | $2.3m | -1.7pp |
| Other | $0.48m | — | −$12.2m | n/a |
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| PBT growth | -59.6% | — | cleaner earnings measure |
| Effective tax rate | 22.0% | 22.5% | — |
| OCF / EBITDA (cash conversion) | -78.5% | -54.2% | deteriorated |
| FCF pre-lease | −$28.7m | −$35.8m | +$7.1m |
| FCF / NPAT | -736.5% | -137.5% | complementary conversion metric |
| Capex % revenue | 1.5% | 1.7% | — |
| Capex | −$4.8m | −$5.3m | +$0.46m |
| Debtor days | 0.2 | 0.3 | -0.2 days |
| Inventory days | 27.5 | 22.8 | +4.7 days |
| Trade debtors | $0.27m | $0.58m | −$0.32m |
| Net debt | $29.8m | $3.2m | +$26.6m |
| Net debt / EBITDA | 0.98x | 0.06x | Weakening |
| Gross borrowings | $67.5m | $39.4m | +$28.1m |
| ROE (annualised) | 1.1% | 6.7% | Weakening |
| HY22 share of FY22 revenue | 50.0% | — | Other half was 50.0% |
| HY22 share of FY22 EBITDA | 82.4% | — | Other half was 17.6% |
| HY22 share of FY22 NPAT | 134.2% | — | Other half was -34.2% |
| Profit from continuing operations | $14.3m | — | — |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.
Source-backed analysis from the filing set attached to this briefing.